2-	18	
	C	

Please type a prus sign (+) inside this box —

PTO/SB/50 (02-01)
Approved for use through 01/31/2004. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERS

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REISSUE PATENT APPLICATION TRANSMITTAL

Address to:	Attorney Docket No.	19526PR					
Assistant Commissioner for Patents	First Named Inventor	R.K. Bakshi					
Box Reissue	Original Patent Number Original Patent Issue Date	6,001,844					
Washington, DC 20231	(Month/Day/Year)	Dec. 14, 1999					
	Express Mail Label No.	EL523908486US					
APPLICATION FOR REISSUE OF: X Utility Patent (Check applicable box)	Design Patent	Plant Patent					
APPLICATION ELEMENTS (37 CFR 1.173)	ACCOMPANYING APP	LICATION PARTS					
1. X Fee Transmittal Form (PTOI SBI 56) 2. Applicant claims small entity status. See 37 CFR 1.27. 3. X Specification and Claims in double column copy of patent format (amended, if appropriate) 4. Drawing(s) (proposed amendments, if appropriate) 5. Reissue Oath/Declaration (original or copy) (37 C.F.R. § 1.175) (PTOI/SBI51 or 52) 6. Power of Attorney 7. Original U.S. Patent currently assigned? X Yes No (If Yes, check applicable box(es)) X Written Consent of all Assignees (PTOI/SBI53) X 37 C.F.R. § 3.73(b) Statement (PTOI/SBI96) 8. C.D.ROM or CD-R in duplicate, Computer Program (Appendix) or large table 10. Statement of status and support for all chang to the claims. See 37 CFR 1.173 (c). Original U.S. Patent for surrender Ribboned Original Patent Grant Statement of Loss (PTOI/SBI55) 12. Foreign Priority Claim (35 U.S.C. 119) (if applicable) 13. X Copies of Statement (IDS)/PTO-1449 Citations 14. English Translation of Reissue Oath/Declarat (if applicable) 15. X Preliminary Amendment 16. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 17. Other: Unsigned Reissue Oath/. Declaration & Power of							
9. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all of the following are necessary) a. Computer Readable Form (CFR)	Attorney						
b. Specification Sequence Listing on: i □ CD-ROM (2 copies) or CD-R (2 copies); or ii □ paper c. □ Statements verifying identity of above copies							
18. CORRESPONDENCE ADDRESS							
Customer Number or Bar Code Label COO2.1 Consert Customer No. or Attach bar code label hereign.							
Name							
Address							
	Zip Code						
City State	Fax						
Country Telephone							
NAME (PantiType) Catherine D. Fitch Registration No. (Attorney/Agent) 36.502							
NAME (PantiType) Catherine D. Fitch		12/1//2001					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Box Reissue, Washington, DC 20231.

To Be Assigned
12/14/2001
R. K. Bakshi
To Be Assigned
To Be Assigned
19526PR

DATE OF DEPOSIT

12/14/2001

EXPRESS MAIL NO.

EL523908486US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY LOTAY Kleithouses DATE 12-14-01

Computer generated form "Miscellaneous Fee Sheet" (FEES Folder), Merck & Co., Inc. 10/01/2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Claims as Filed - Part 1 Claims as Filed - Part 1 Rate Fee Rate Fee Rate Fee (A) 13 (37 GFR 1.16(ii) (37 GFR 1.16(ii)) (38 GF	REISSUE APPLICATION FEE TRANSMITTAL FORM					Docket Number (Optional) 19526PR					
Patent Role Roles Patent Role Role Role Rate Rate Fee Rat											
(A) 13 (37 CFR 1.16(i)) (B) 13 (37 CFR 1.16(ii)) (C) 2 (37 CFR 1.16(ii)) (D) 3 (37 CFR 1.16(ii)) (D) 4 (37 CFR 1.16(ii)) (D) 4 (37 CFR 1.16(ii)) (D) 5 (37 CFR 1.16(ii)) (D) 6			Numb					ntity	ty Other than a Small Entity		
(A) 1.3 (37 CFR 1.16(j)) (B) 1.3	Patent	TitlOli	Reissue	Application	Nun		Rate	Fee		Rate_	Fee
CC 2 Independent claims CD 2	(A) 13		(B)	13	***		x \$=			x \$=	0
Basic Fee (37 CFR 1.16(h)) \$ \$ 740 Claims as Amended - Part 2 (1) (2) (3) Small Entity Other than a Small Entity Previously Paid For Present Claims Fee Rate Fee Rate Fee Rate Fee Rate Fee Rate Fee Individual Fee Rate	(c) 2	Independent claims	(D)	2	*	0 =	x \$ =		or		^
Total Filing Fee \$ OR \$ 740 Claims as Amended - Part 2 (1) (2) (3) Small Entity Other than a Small Entity Previously Paid For Present Previously Paid For Present Total Claims Tota		(37 CFR 1 16(i))		i	<u> </u>					X\$=	
Claims as Amended - Part 2 (1) (2) Highest Number Previously Paid For Previously Present Rate Fee Rate Fee Rate Fee Paid For Previously Paid For Previously Present Previously Present Rate Fee Rate Fee Rate Fee Paid For Previously Present Previously Present Previously Present Rate Fee Rate Fee Rate Fee Paid For Previously Present Previously Present Previously Present Previously Present Previously Previous P						•		\$			\$_740
Claims Remaining After Amendment Highest Number Previously Paid For State Fee Rate F					To	otal Filing F	ee	\$		OR	\$ 740
Claims Remaining After Amendment Total Claims Total Clai			· • · · · · · · · · · · · · · · · · · ·	Claims	s as Ar	mended - P	art 2				
After Amendment Previously Paid For Present Fee Rate Fee Rate Fee Total Claims Total Claims 18 MINUS 20 *= 0 x \$ =					mher		Small E	Entity		Other than	a Small Entity
18	•			Previous	ly	Claims Present	Rate	Fee		Rate	Fee
*If the entry in (D) is less than the entry in (C), Write "0" in column 3. **If the "Highest Number of Total Claims Previously Paid For" is less than 20, Write "20" in this space. ***After any cancellation of claims. ****If "A" is greater than 20, use (B - A); if "A" is 20 or less, use (B - 20). ***********************************			MINUS			=	×\$=			× \$=	= 0
* If the entry in (D) is less than the entry in (C), Write "0" in column 3. ** If the "Highest Number of Total Claims Previously Paid For" is less than 20, Write "20" in this space. **** After any cancellation of claims. **** After any cancellation of claims. **** After any cancellation of claims. **** If "A" is greater than 20, use (B - A); if "A" is 20 or less, use (B - 20). ***** "Highest Number of Independent Claims Previously Paid For" or Number of Independent Claims in Patent (C). Applicant claims small entity status. See 37 CFR 1.27. Please charge Deposit Account No. 13–2755 in the amount of \$740.00 Aduplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required, or credit any overpayment to Deposit Account No. 13–2755 Aduplicate copy of this sheet is enclosed. A check in the amount of \$		*** 2	MINUS	***** 2		= 0	x\$=			×\$=	= O
* If the entry in (D) is less than the entry in (C), Write "0" in column 3. ** If the "Highest Number of Total Claims Previously Paid For" is less than 20, Write "20" in this space. *** After any cancellation of claims. *** After any cancellation of claims. *** After any cancellation of claims. *** If "A" is greater than 20, use (B - A); if "A" is 20 or less, use (B - 20). **** "Highest Number of Independent Claims Previously Paid For" or Number of Independent Claims in Patent (C). Applicant claims small entity status. See 37 CFR 1.27. Please charge Deposit Account No. 13-2755 in the amount of \$740.00 Aduplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required, or credit any overpayment to Deposit Account No. 13-2755 Aduplicate copy of this sheet is enclosed. A check in the amount of \$						Total A	dditional Fee	\$	7	OR	\$ 740
December 14, 2001 Date Signature of Applicant, Attorney or Agent of Record											

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue

Application

of:

U.S. Patent No. 6,001,844

Applicants:

Bakshi et al.

Reissue

Serial No.:

To Be Assigned

Case No.: 19526PR

Art Unit:

To be Assigned

Filed:

December 14, 2001

For:

4-AZASTEROIDS FOR TREATMENT OF

HYPERANDROGENIC CONDITIONS

Examiner:

To be Assigned

BOX REISSUE

Assistant Commissioner for Patents Washington, D.C. 20231

ASSENT BY ASSIGNEE FOR FILING OF REISSUE APPLICATION, OFFER TO SURRENDER ORIGINAL PATENT AND STATEMENT UNDER 37 C.F.R. 3.73(b)

Sir:

This is part of the application for a reissue patent filed herewith based on the original U.S. Patent No. 6,001,844, issued December 14, 1999.

U.S. Patent No. 6,001,844 is assigned to Merck & Co., Inc. as assignee of the entire right, title and interest in said patent by virtue of an assignment recorded at Reel/Frame 010117/0047 on July 26, 1999.

Merck & Co., Inc. hereby consents to the accompanying application for reissue of U.S. Patent No. 6,001,844.

Reissue Serial No.: To Be Assigned

Reissue of:

US 6,001,844 19526PR

Case No.: Page No.:

2

Merck & Co., Inc. hereby offers to surrender U.S. Patent 6,001,844, when the reissue application is otherwise in condition for allowance.

The undersigned, whose title is supplied below, is empowered to sign this document on

behalf of the assignee.

Date

Melvin Winokur Counsel, Patents

Encl.: Corp. Resolution #5

DATE OF DEPOSIT December 14, 2001 EXPRESS MAIL NO. EC52390818645

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER

FOR PATENTS, WASHINGTON, D.C., 20231

DATE

CERTIFICATION

I, Debra A. Bollwage, Assistant Secretary of Merck & Co., Inc., a Corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the attached, presently in full force and effect, is a true and correct copy of General Corporate Resolution #5, Patent Matters, as amended by Unanimous Written Consent of the Board of Directors of said Corporation on April 24, 2001.

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Corporation this 27th day of April, 2001.

Debra A. Bollwage Assistant Secretary

(SEAL)

General Corporate Resolution #5

PATENT MATTERS

RESOLVED, that any of the following:

Raymond V. Gilmartin-Chairman of the Board, President and Chief Executive Officer Kenneth C. Frazier-Senior Vice President and General Counsel Joseph F. DiPrima-Vice President and Assistant General Counsel Paul D. Matukaitis-Vice President and Assistant General Counsel Edward W. Murray-Counsel, Litigation Charles M. Caruso-Counsel, International W. Gwyn Cole-Counsel-European Patents Mark R. Daniel-Counsel, Patents David L. Rose-Counsel, Patents Jack L. Tribble-Counsel, Patents Alevin Winokur-Counsel, Patents Richard C. Billups-Assistant Counsel, Patent Practices Donna L. Margiotto-Administrator, Patents

are authorized to execute and to revoke on behalf of Merck & Co., Inc. and its affiliates (including subsidiaries) the following documents relating to patent matters:

Powers of attorney as fully in law as may be necessary and proper in connection with the acquisition, registration, maintenance and enforcement of patents and applications for patents, including powers of attorney relating to the prosecution or defense of patent rights before courts of law or other governmental tribunals, agencies or departments; affidavits and declarations; and any other documents which are necessary and proper for the acquisition, registration, maintenance, litigation and protection of patents.